

Transgene expands its Oncology pipeline with a novel drug for Colon Cancer

April 22, 2010

Transgene Biotek announced today the addition of another novel drug to its existing cancer drug pipeline. This drug for Colon Cancer is based on its proprietary new technology platform that uses a humanized monoclonal antibody (mAb).

Cancer accounted for 7.9 million deaths in 2007 according to the WHO Factsheet, July 2008. The recently published report from the Economist Intelligence Unit on the Global Burden of Cancer indicates that, by 2020, 9.7% of new cases of cancer in the world will be from Colorectal Cancer, making it the third highest incidence cancer after Lung and Breast.

For the past several years, Transgene has been involved in designing novel anti-cancer therapeutics. Now they have developed a monoclonal antibody that specifically kills Colon Cancer cells without harming normal cells. Transgene's drug development for their monoclonal antibody platform is based on generating monoclonal antibodies against a designed peptide from the sequence of a specific cell surface antigen that is expressed specifically on Colon Cancer cells and not on normal cells. Recent in-vitro studies of the antibody for Colon Cancer have clearly established its specificity, and have proved that it is an excellent cancer target drug. Work is progressing to identify other cancers that may be amenable for treating with the same antibody.

With the in-vitro study data demonstrating a highly positive response, Transgene is advancing this drug for complete humanization, in preparation for pre-clinical and clinical studies.